Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0HS5V
|
|||
| Former ID |
DNCL002613
|
|||
| Drug Name |
Brivanib
|
|||
| Synonyms |
Brivanib; 649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [1], [2] | |
| Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 3 | [1], [2] | ||
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H19FN4O3
|
|||
| Canonical SMILES |
CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)O)C
|
|||
| InChI |
1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
|
|||
| InChIKey |
WCWUXEGQKLTGDX-LLVKDONJSA-N
|
|||
| CAS Number |
CAS 649735-46-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16317953, 23414456, 42313638, 77365611, 92721417, 99436978, 103483726, 104069124, 124490329, 124756986, 125163791, 126619161, 126661321, 126661731, 126730839, 131480673, 134343564, 134964399, 135252957, 135727386, 136367284, 136368025, 136377882, 136920387, 137276004, 141643704, 144115752, 152059805, 152088878, 152258181, 152344141, 160647017, 162011436, 162029696, 162110616, 162200058, 164041879, 164775472, 170500439, 174475086, 174539891, 177748734, 178102299, 180404088, 184816398, 188899522, 198948130, 223573483, 223677759, 223705289
|
|||
| ChEBI ID |
CHEBI:94562
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5671). | |||
| REF 2 | ClinicalTrials.gov (NCT01108705) Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment. U.S. National Institutes of Health. | |||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.